Asuragen, Inc. To Join Leading UK Cancer Research Consortium To Develop Mirna Based Sequencing Tests For Early Detection And Screening Of Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc., a leading molecular diagnostic company, has been selected to work with the Early Diagnosis Consortium (EDC), a collaboration between Cancer Research UK, Cancer Research Technology, and Abcodia. The Consortium aims to discover and validate serum biomarkers that may be used in screening and early detection of cancer.
Asuragen will use its proprietary small RNA sequencing workflow and bioinformatics pipeline that has been optimized specifically for identification of miRNA, isomiRs, and other similarly sized small ncRNA candidate biomarkers from biofluid samples. This work will support EDC’s discovery of circulating miRNA biomarkers that could lead to diagnostics for early detection of malignancies across colorectal, lung, esophageal, and pancreatic cancers.
Help employers find you! Check out all the jobs and post your resume.
Asuragen will use its proprietary small RNA sequencing workflow and bioinformatics pipeline that has been optimized specifically for identification of miRNA, isomiRs, and other similarly sized small ncRNA candidate biomarkers from biofluid samples. This work will support EDC’s discovery of circulating miRNA biomarkers that could lead to diagnostics for early detection of malignancies across colorectal, lung, esophageal, and pancreatic cancers.
Help employers find you! Check out all the jobs and post your resume.